Pharmacokinetic (PK) and pharmacocokinetic/pharmacodynamic characterization of the two-drug anti-retroviral regimen (2DR) dolutegravir/rilpivirine following switch from current anti-retroviral therapy in the SWORD-1 and SWORD-2 Phase 3 studies

Abstract